Regulatory and shareholder probes target Corcept Therapeutics over relacorilant FDA communications

Regulatory disclosure probes target Corcept over relacorilant communications

Regulatory and shareholder-rights law firms are opening parallel investigations into Corcept Therapeutics after the U.S. Food and Drug Administration issues a Complete Response Letter for relacorilant, the company’s investigational treatment for hypertension secondary to hypercortisolism. The FDA acknowledges that Corcept’s pivotal GRACE trial meets its primary endpoint and that data from the GRADIENT trial provide confirmatory evidence, but concludes it cannot reach a favorable benefit‑risk assessment without additional evidence of effectiveness. The CRL is dated December 31, 2025.

The probes focus on whether Corcept, its executives or directors made false or misleading statements or omitted material facts about relacorilant’s development, the strength and interpretation of GRACE and GRADIENT data, communications with the FDA, and internal analyses that could have affected investor perceptions. The Schall Law Firm and DJS Law Group say they are investigating potential securities‑law violations and are inviting affected shareholders to contact them to explore participation in collective legal action.

The investigations underline heightened scrutiny on how small biotechs disclose regulatory interactions and clinical results for niche endocrine therapies. Lawyers say potential class actions could hinge on internal timelines, company-to-regulator correspondence and contemporaneous investor communications. For the wider industry, the episode underscores that regulators may accept positive pivotal outcomes yet still require additional demonstration of clinical effectiveness or benefit‑risk balance before granting approval, prompting firms to be precise in communicating trial nuances.

Law firms announce outreach and services

The Schall Law Firm, based in Los Angeles, and DJS Law Group, based in Eastchester, New York, both issue press notices offering free consultations and urging shareholders who suffered losses to preserve documents. Each firm notes experience in securities class actions and cautions that their releases may constitute Attorney Advertising under local rules; they provide contact details for prospective clients.

Context on relacorilant and next steps

Relacorilant remains investigational for hypertension secondary to hypercortisolism, a rare endocrine condition, and the FDA’s request for additional evidence leaves Corcept with options including supplemental trials, additional analyses, or further discussions with regulators. The companies’ filings and subsequent disclosures will be closely watched by regulators, investors and potential plaintiffs as the legal reviews proceed.